Enobia Pharma
Date | Investors | Amount | Round |
---|---|---|---|
$15.6m | Series A | ||
$40.1m | Series B | ||
$50.0m | Series C | ||
N/A | $15.0m | Late VC | |
N/A | $40.0m | Late VC | |
N/A | Acquisition | ||
Total Funding | AUD248m |
Recent News about Enobia Pharma
EditEnobia operates in the mental health and wellness sector, providing an extensive online therapy platform that specializes in Cognitive Behavioral Therapy (CBT). The company serves individuals seeking mental health support, including those dealing with conditions such as ADHD, hypophosphatasia, and Oppositional Defiant Disorder (ODD). Enobia's market includes both direct consumers and healthcare providers looking for effective, evidence-based therapeutic solutions. The business model is subscription-based, where clients pay for access to therapy sessions, personalized guidance from licensed therapists, and a variety of mental health resources. Revenue is generated through these subscriptions as well as potential partnerships with healthcare institutions. Enobia's unique selling proposition lies in its comprehensive, evidence-based CBT programs and the convenience of online access, making mental health support more accessible and affordable.
Keywords: Cognitive Behavioral Therapy, online therapy, mental health, ADHD, hypophosphatasia, ODD, personalized guidance, subscription-based, evidence-based, healthcare partnerships.